Martin Dietrich, MD, PhD

The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.

Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Martin Dietrich, MD, PhD, details the molecular target CEACAM5 and its use in the treatment of patients with non-small cell lung cancer.

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.